- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05610033
Pilot evaluatIon Of NovEl tEmpoRary ExtraVascular PACING (PIONEER EV PACING) Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary safety endpoint is freedom from Adverse Device Effects, CTCAE Grade 3 or higher. The primary performance endpoint is percentage of Subjects with demonstrated pacing capture following lead fixation.
Up to 30 subjects will be enrolled at up to three (3) investigation centers. Enrolled subjects will undergo insertion of a StealthTrac Lead within one calendar day of an eligible planned index procedure that requires a temporary pacing lead. Echocardiographic evaluations will be performed before and after StealthTrac Lead insertion, as well as after the index procedure, to assess for pericardial effusion. Post-operative fluoroscopic images are required in all subjects to document the final lead position. In subjects without an underlying ventricular escape rhythm, a concomitant, commercially available pacing lead is required. Lead measurements (Thresholds, Impedance, R-Waves) and an insertion procedure survey will be obtained.
Subjects will be restricted to bed rest while the StealthTrac lead remains inserted. The StealthTrac Lead will be connected to a commercially available, constant-current temporary pacemaker programmed by the investigator to provide temporary pacing support. The StealthTrac Lead will remain inserted until the next calendar day, at a minimum, and will be removed once the clinical need for temporary pacing ends. The maximum duration of lead insertion is two (2) days following the lead insertion procedure.
Follow up evaluations will be performed for as long as the StealthTrac Lead remains inserted. Subjects will also undergo a 30-day post-removal follow-up before completing participation. On the final follow-up, prior to StealthTrac Lead removal, Subjects may be tested in multiple postures. Subjects with pacing capture in the upright posture may have ECGs recorded during various isometrics or while walking with pacing from the StealthTrac Lead.
Prior to removal, a final lead evaluation will be performed and fluoroscopy will be used to document the final lead position. Echocardiographic imaging will be obtained before and after the removal procedure to characterize any new or worsened pericardial effusions. A final post-removal follow-up will be performed in person or remotely to document any latent adverse events.
The overall study is expected to last four (4) months, comprising two (2) months for enrollment and follow-up and two (2) months to monitor study data and prepare a final report.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Michael Husby, MS, MPH
- Phone Number: +1 949-392-8988
- Email: michael@atacor.com
Study Contact Backup
- Name: Sarah Hase, BS, CCRA
- Phone Number: +1 949-545-9820
- Email: sarah@atacor.com
Study Locations
-
-
-
Split, Croatia, 21000
- Recruiting
- University Hospital Center Split
-
Contact:
- Ante Anic, MD
- Phone Number: 385 99 2338 009
- Email: anteanic@gmail.com
-
Principal Investigator:
- Ante Anic, MD
-
-
-
-
-
Prague, Czechia
- Not yet recruiting
- Na Homolce Hospital
-
Contact:
- Marko Tichý
- Phone Number: +420 257 272 376
- Email: Marko.Tichy@homolka.cz
-
Principal Investigator:
- Petr Neužil, Prof. MUDr. CSc., FESC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria
- At least 18 years old
Subjects who:
Are undergoing one of the following planned (non-urgent) procedures that are associated with the potential need for temporary bradycardia pacing:
- Transarterial transcatheter aortic valve implantation (TAVI)
- Transarterial balloon aortic valvuloplasty (BAV)
- Cardiovascular implantable electronic device (CIED) pulse generator replacement
- Cardiovascular implantable electronic device (CIED) lead extraction OR
- Subjects with bradycardia who are under evaluation to determine if the cause is transient or permanent
Exclusion criteria
- BMI ≥ 35 kg/m2
- Septic shock
- Severe anemia
- Patients on dual antiplatelet therapy or anti-coagulation that cannot be stopped for the procedure
- Circumstances that prevent data collection or follow-up
- Participation in any concurrent clinical study without prior written approval from the Sponsor
Inability or unwillingness to provide informed consent to participate in the Study
Known prior history for any of the following:
- Median or partial sternotomy
- Acute coronary syndrome within past 90 days
- NYHA Functional Classification IV within past 90 days
- Surgically corrected congenital heart disease (not including catheter-based procedures)
- Allergies to the device materials such as stainless steel, titanium, platinum, iridium, polyethylene, polyurethane, polycarbonate and silicone
- Surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium, including adhesions
- Significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis)
- Thoracic radiation therapy, pneumothorax, pneumomediastinum or other medical treatments which may complicate the AtaCor EV Temporary Pacing Lead System insertion procedure
- Any conditions which may complicate the AtaCor EV Temporary Pacing Lead System insertion procedure
- Pericardial disease, pericarditis and mediastinitis
- Medical treatments, surgeries or conditions that increase the potential for pericardial adhesions
- FEV1 < 1 liter
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AtaCor EV Temporary Pacing Lead System
Subjects implanted with the AtaCor StealthTrac Lead Model AC-101400
|
Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from severe ADEs
Time Frame: Up to 30 days post-lead removal
|
Freedom from Adverse Device Effects, CTCAE Grade 3 or Higher
|
Up to 30 days post-lead removal
|
Percentage of Subjects with pacing capture
Time Frame: Up to 2 days post-lead insertion
|
Percentage of Subjects with demonstrated pacing capture following lead fixation
|
Up to 2 days post-lead insertion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Martin C Burke, DO, AtaCor Medical, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DOC-10219
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Conduction Defect
-
AtaCor Medical, Inc.Recruiting
-
AtaCor Medical, Inc.Completed
-
AtaCor Medical, Inc.Completed
-
AtaCor Medical, Inc.CompletedConduction DefectNew Zealand, Paraguay, Czechia
-
AtaCor Medical, Inc.Completed
-
Assiut UniversityUnknown
-
Nantes University HospitalRecruitingCongenital Complete Heart Block | Cardiac Conduction Defect ProgressiveFrance
-
Maastricht University Medical CenterActive, not recruitingHeart Diseases | Cardiac Conduction DefectNetherlands
-
Imperial College LondonCompletedLeft Bundle-Branch Block | Right Bundle-Branch Block | Non-Specific Intraventricular Conduction DefectUnited Kingdom
-
Imperial College LondonCompletedHeart Failure | Left Bundle-Branch Block | Left Ventricular Systolic Dysfunction | Right Bundle-Branch Block | Non-Specific Intraventricular Conduction DefectUnited Kingdom
Clinical Trials on AtaCor StealthTrac Lead
-
AtaCor Medical, Inc.Recruiting
-
AtaCor Medical, Inc.Completed
-
AtaCor Medical, Inc.CompletedConduction DefectNew Zealand, Paraguay, Czechia
-
AtaCor Medical, Inc.CompletedVentricular Fibrillation | Ventricular Tachycardia | Ventricular ArrhythmiaParaguay
-
AtaCor Medical, Inc.CompletedVentricular Fibrillation | Ventricular Tachycardia | Ventricular ArrhythmiaParaguay
-
AtaCor Medical, Inc.CompletedVentricular Fibrillation | Ventricular Tachycardia | Ventricular ArrythmiaParaguay
-
AtaCor Medical, Inc.Completed
-
Abbott Medical DevicesCompletedAtrial Fibrillation | TachyarrhythmiasUnited States
-
Aarhus University Hospital SkejbyDanish Heart FoundationCompletedAtrioventricular BlockDenmark
-
Huawei Device Co., LtdCompletedArrhythmias, CardiacChina